GPT and hepatocellular carcinoma: While the incidence of ≥ grade 3 ALT elevation in patients treated with Nivolumab for HCC was 8% in an initial trial (Checkmate 040) (28), the reported incidence of a similar increase in major trials for lung cancer was 0% (29–31) and ranged from 0-4% in trials for melanoma (32–35).